TCTMD’s Top 10 Most Popular Stories for November 2019
AHA 2019 stories dominated this month’s list, led by the landmark ISCHEMIA trial.
More than half of our top 10 stories for November stemmed from the American Heart Association 2019 Scientific Sessions, led by the blockbuster ISCHEMIA trial. Also on the list were two recent moves by the Centers for Medicare & Medicaid Services (CMS): the first was the CMS decision to allow reimbursement of PCIs performed at ambulatory surgical centers, while the second covers CMS cuts to payments for cardiac CT. Rounding out the top 10 was a story from the VIVA meeting looking at radiation in the cath lab and a study addressing the role of upfront cardiac MRI and CT to reduce the number of invasive angiograms in patients with an unclear NSTEMI diagnoses.
Both the “expanded” endpoint and death/MI were no different between arms, but QoL was significantly better with PCI/CABG.
Angiography remains “essential” but its timing is not, long-term COACT data confirm.
Experts point to pitfalls in these kinds of data and say halting Impella use is not the answer—quality and patient selection are key.
The results in this high-risk population show no impact on clinical outcomes or quality of life.
Seen as a possible way to save money, the rule, supported by the ACC and SCAI, will go into effect on January 1, 2020.
Randomized trials will be needed to confirm these findings, physicians said at AHA 2019.
In response, professional societies like SCCT, ACC, and ACR are committing to continued advocacy efforts.
Chest pain, a positive hs-cTnT, and a nondiagnostic ECG together pose a quandary for physicians. A study suggests CMR and CTA can help.
Awareness of surroundings and others in the room are key to proper cath-lab radiation safety, a VIVA “roundtable” concluded.
Compared with placebo, the novel siRNA injectable reduced LDL cholesterol by 56% over 18 months.
* * * * *
SEE ALSO: Our top ‘opinion’ piece of November 2019 was our latest Conversations in Cardiology, hosted by Morton Kern, MD. Top in Features was a story by Yael Maxwell on the concerns over subtherapeutic heparin.
Morton Kern, MD, engages his colleagues via email in brief, informal dialogue on clinically relevant topics in interventional cardiology.
Reports are widespread about operators having trouble reaching adequate ACTs, but the FDA has not yet confirmed a problem.